Todays Report: The Stillwater Investment Management LLC Sold shares of Merck & Co. (MRK)

The Stillwater Investment Management LLC Sold shares of Merck & Co. (MRK)

Stillwater Investment Management LLC lowered its position in Merck & Co. (NYSE:MRK) by 1.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,521 shares of the company’s stock after selling 82 shares during the period. Stillwater Investment Management LLC’s holdings in Merck & Co. were worth $345,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of MRK. QCI Asset Management Inc. NY boosted its position in shares of Merck & Co. by 1.1% in the second quarter. QCI Asset Management Inc. NY now owns 2,382 shares of the company’s stock worth $137,000 after buying an additional 27 shares during the last quarter. Annex Advisory Services LLC boosted its position in shares of Merck & Co. by 0.4% in the second quarter. Annex Advisory Services LLC now owns 12,081 shares of the company’s stock worth $696,000 after buying an additional 43 shares during the last quarter. Landmark Financial Advisors LLC boosted its stake in shares of Merck & Co. by 0.7% in the second quarter. Landmark Financial Advisors LLC now owns 6,393 shares of the company’s stock valued at $368,000 after buying an additional 43 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Merck & Co. by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 5,234 shares of the company’s stock valued at $302,000 after buying an additional 44 shares during the last quarter. Finally, Cornerstone Advisors Inc. boosted its stake in shares of Merck & Co. by 0.9% in the second quarter. Cornerstone Advisors Inc. now owns 4,849 shares of the company’s stock valued at $279,000 after buying an additional 45 shares during the last quarter. 73.25% of the stock is owned by institutional investors.

Shares of Merck & Co. (NYSE:MRK) traded up 0.92% during mid-day trading on Friday, hitting $62.21. The company had a trading volume of 3,501,268 shares. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $65.46. The firm has a market capitalization of $171.52 billion, a PE ratio of 31.77 and a beta of 0.76. The firm has a 50-day moving average price of $61.63 and a 200-day moving average price of $60.02.

Merck & Co. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, October 25th. The company reported $1.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.08. The business had revenue of $10.50 billion for the quarter, compared to analysts’ expectations of $10.17 billion. Merck & Co. had a return on equity of 24.25% and a net margin of 13.76%. The business’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.96 EPS. Equities analysts forecast that Merck & Co. will post $3.78 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 9th. Shareholders of record on Thursday, December 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 3.02%. This is a boost from Merck & Co.’s previous quarterly dividend of $0.46. The ex-dividend date is Tuesday, December 13th. Merck & Co.’s payout ratio is presently 93.88%.

Several equities research analysts have recently weighed in on the company. Piper Jaffray Cos. reissued a “neutral” rating and issued a $62.00 price target (up previously from $58.00) on shares of Merck & Co. in a research note on Monday, August 8th. Vetr cut Merck & Co. from a “buy” rating to a “hold” rating and set a $64.84 price target for the company. in a research note on Monday, October 10th. Zacks Investment Research raised Merck & Co. from a “hold” rating to a “buy” rating and set a $70.00 price target for the company in a research note on Thursday, November 17th. Bank of America Corp. raised Merck & Co. from a “neutral” rating to a “buy” rating and increased their price target for the company from $57.00 to $70.00 in a research note on Thursday, October 13th. Finally, Argus reissued a “buy” rating and issued a $65.00 price target on shares of Merck & Co. in a research note on Wednesday, September 14th. Thirteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Merck & Co. presently has a consensus rating of “Hold” and a consensus price target of $66.24.

In other Merck & Co. news, Chairman Kenneth C. Frazier sold 140,000 shares of Merck & Co. stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $65.03, for a total transaction of $9,104,200.00. Following the sale, the chairman now directly owns 514,957 shares of the company’s stock, valued at approximately $33,487,653.71. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Rochelle B. Lazarus sold 20,000 shares of Merck & Co. stock in a transaction that occurred on Wednesday, November 2nd. The shares were sold at an average price of $59.06, for a total value of $1,181,200.00. Following the sale, the director now directly owns 9,594 shares in the company, valued at $566,621.64. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.

About Merck & Co.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Related posts

Leave a Comment